What is IRWD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.63B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IRWD?

P/E (TTM) is 4.91 and 52-week range is $1.41 to $5.78 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IRWD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IRWD?

The company profile lists revenue (TTM) near $383M, net income (TTM) near $128M, EPS (TTM) near $0.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ironwood Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 164.6M shares outstanding, ISIN US46333X1081 when available from company profile and filing metadata.

Ironwood Pharmaceuticals Inc

$IRWD

Health Care · Biotechnology

IR Run Scenarios

$3.82

-1.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Employees

100

Website

www.ironwoodpharma.com/

IPO

2010-02-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)